BioMarin Pharmaceutical Signs Agreement To Acquire Alesta Therapeutics For $275M
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) announced today that BioMarin has entered into a definitive agreement to acquire Alesta Therapeutics to gain Alesta's lead clinical-stage asset, ALE1. Alesta plans to spin
BioMarin is buying another smaller company called Alesta to get a medicine they're working on. When big companies buy smaller ones to get new medicines, it shows they're trying to grow and help more patients.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.